Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David Wyles, Paul Pockros, Giuseppe Morelli, Ziad Younes, Evguenia Svarovskaia, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, John G. McHutchison, Steven Flamm, Eric Lawitz – 2 April 2015 – Patients who fail to achieve sustained virological response (SVR) after treatment with sofosbuvir (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg‐IFN) do not have established retreatment options.